Low dose of clozapine in the treatment of dopaminergic psychosis in Parkinson's disease

Clinical Neuropharmacology

Volumn 20, Issue 3, 1997, Pages 204-209

  Ruggieri, S ^a   De Pandis, M F ^b   Bonamartini, A ^b   Vacca, L ^b   Stocchi, F ^a,b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b Mediterranean Institute of Neuroscience   (Italy)

Author keywords

Clozapine; Dopaminergic psychosis; Parkinson's disease

Indexed keywords

APOMORPHINE; CLOZAPINE; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DELUSION; DOSE CALCULATION; DREAM; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL SYMPTOM; HALLUCINATION; HUMAN; HYPOTENSION; MALE; ORAL DRUG ADMINISTRATION; PARANOIA; PARKINSON DISEASE; PRIORITY JOURNAL; PSYCHOSIS; SEDATION; SEXUAL DYSFUNCTION; SUBCUTANEOUS DRUG ADMINISTRATION; VERTIGO;

EID: 0030948652     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002826-199706000-00003     Document Type: Article

References (27)

1. Damasio AR, Lobo-Antunes J, Macedo C. Psychiatric aspects in parkinsonism treated with l-dopa. J Neurol Neurosurg Psychiatry 1971;34:502-7.
2. Moskovitz C, Moses H, Klawans HL. Levodopa induced psychosis: a kindling phenomenon. Am J Psychiatry 1978;135:669-75.
3. Celesia GG, Barr AN. Psychosis and other psychiatric manifestations of levodopa therapy. Arch Neurol 1970;23:193-200.
4. Lees AJ, Stern GM. Sustained bromocriptine therapy in previously untreated patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 1981;44:1020-3.
5. Goodwin FK. Psychiatric side effects of levodopa in man. JAMA 1971;218:1915-20.
6. Goetz CG, Tanner CM, Klawans HL. Pharmacology of hallucinations induced by long-term drug therapy. Am J Psychiatry 1982;139:494-7.
7. Baldessarini RJ, Frankenburg FR. Clozapine: a novel antipsychotic agent. N Engl J Med 1991;324:746-54.
8. Tully EM. Clozapine: a review. Am J Prev Psychiatr Neurol 1988;1:19-23.
9. Rebec JV, Bashor TR, Zimmerman KS, Alloway KD. Classical and atypical antipsychotic drugs: differential antagonism of amphetamine and apomorphine-induced alterations of spontaneous neuronal activity in the neostriatum and nucleus accumbens. Pharmacol Biochem Behav 1979;11:529.
10. 2 dopamine receptor-mediated behaviors. Eur J Pharmacol 1989;159:141-7.
11. Seeger TF, Thal L, Gardner EL. Behavioural and chemical aspects of neuroleptic-induced dopaminergic supersensitivity: studies with chronic clozapine and haloperidol. Psychopharmacology 1982; 76:182-7.
12. 1 receptor. J Neurochem 1986;47:1822-31.
13. Kane JM, Cooper TB, Sachar EJ, Halpern FS, Bailine S. Clozapine: plasma levels and prolactin response. Psychopharmacology 1981;73:184-7.
14. 2 dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs. Arch Gen Psychiatry 1988;45:71-6.
15. Farde L, Nordstrom AL. PET analysis indicated atypical central dopamine receptor occupancy in clozapine-treated patients. Br J Psychiatry 1992;160:30-3.
16. Cattabeni F, Algeri S, Coen E, et al. Measurement of dopaminergic and noradrenergic functional activity through 3-methoxy-tyramine and normetanephrine. In: Hanin I, ed. Dynamics of neurotransmitter function. New York: Raven Press, 1984:11-9.
17. Factor SA, Brown D. Clozapine prevents recurrence of psychosis in Parkinson's disease. Mov Disord 1992;7:125-31.
18. Wolters EC, Hurwitz TA, Peppard RF, Calne DB. Clozapine: an antipsychotic agent in Parkinson's disease? Clin Neuropharmacol 1989;12:83-90.
19. Wolters EC, Hurwitz TA, Mak E, et al. Clozapine in the treatment of parkinsonian patients with dopaminemimetic psychosis. Neurology 1990;40:832-4.
20. Fahn S, Elton RL, members of the UPDRS Development Committee. Unified Parkinson's Disease Rating Scale. In: Fahn S, Marsden CD, Calne D, Goldstein M, eds. Recent developments in Parkinson's disease. Florham Park: MacMillan Healthcare Information, 1987:153-63.
21. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967;17:427-42.
22. Overall J, Gorham D. Brief Psychiatric Rating Scale, Psychol Rep 1962;10:799-818.
23. Factor SA, McAlarney T, Sanchez-Ramos JR, Weiner WJ. Sleep disorders and sleep effect in Parkinson's disease. Mov Disord 1990;5:280-5.
24. Folstein MF, Folstein SE, McHugh PR. "Mini-Mental Status." A practical method for grading the cognitive state of patients for the physician. J Psychiatr Res 1975;12:189-98.
25. Idanpaan-Heikkila J, Alhava E, Olkinoura M, Palva IP. Agranulocytosis during treatment with clozapine. Eur J Clin Pharmacol 1987;11:193-8.
26. Caine ED, Polinsky RJ, Kartzinel R, Hebert MH. The trial use of clozapine for abnormal involuntary movement disorders. Am J Psychiatry 1979;163:317-20.
27. Trugman JM, Leadbetter R, Zalis ME, Burgdorf RO, Wooten GF. Treatment of severe axial tardive dystonia with clozapine: case report and hypothesis. Mov Disord 1994;9:441-6.